<DOC>
	<DOCNO>NCT02147860</DOCNO>
	<brief_summary>The overall aim propose research determine safety , feasibility efficacy Diabetes Assistant ( DiAs ) controller day night closed-loop control child adolescent type 1 diabetes multiple day diabetes camp set . This address two part : 1 ) An residence , outpatient study determine safety feasibility DiAs 72 continuous hour day night glucose control ; 2 ) Camp study plan summer 2014 randomization either full closed-loop sensor-augmented pump therapy duration 6-7 day diabetes camp .</brief_summary>
	<brief_title>Full Day Night Closed-Loop With DiAs Platform</brief_title>
	<detailed_description>This study early feasibility study test efficacy DiAs - smart-phone-based system compare sensor augment therapy outpatient set . Twelve study subject type 1 diabetes , six UVa Stanford University , experience insulin pump use two clinical site recruit . The first six subject recruit age 15-18 year follow recruitment six subject age 10-14 year . This study design mimic protocol camp include period light exercise breakfast moderate intensity physical activity lunch , group activity soccer volleyball . The duration Outpatient Residence Study 72 hour . The data review Data Safety Monitoring Board ( DSMB ) proceed camp study . The camp study recruit 48 subject , type 1 diabetes experience insulin pump therapy . Initial study conduct camp old participant age 15-35 year , least 5 camper 15-18 year old . These study review DSMB , safe , recruit additional child age 10-14 year age . The duration Diabetes Camp Studies 7 days/6 night .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>To eligible study , subject must meet following criterion : 1 . Clinical diagnosis type 1 diabetes The diagnosis type 1 diabetes base investigator 's judgment C peptide level antibody determination require 2 . Daily insulin therapy ≥ 12 month 3 . Insulin pump therapy ≥ 3 month 4 . Age 10.0 35.0 year 5 . Avoidance acetaminophencontaining medication ( i.e . Tylenol ) wear continuous glucose monitor . 6 . Willingness wear continuous glucose sensor physiological monitor duration study 7 . Female subject sexually active must acceptable method contraception ( e.g . oral contraceptive pill , diaphragm , IUD ) The presence follow exclusion study : 1 . Diabetic ketoacidosis past month 2 . Hypoglycemic seizure loss consciousness past 3 month 3 . History seizure disorder ( except hypoglycemic seizure ) 4 . History heart disease include coronary artery disease , heart failure , arrhythmias 5 . Cystic fibrosis 6 . Current use oral glucocorticoid , betablockers medication , judgment investigator would contraindication participation study . 7 . History ongoing renal disease ( microalbuminuria ) . 8 . Subjects require intermediate longacting insulin ( NPH , Detemir Glargine ) . 9 . Subjects require antidiabetic medication insulin ( oral injectable ) . 10 . Pregnancy verbal denial pregnancy obtain telephone informed consent , pregnancy test perform camp study device assign . 11 . Sexually active female practice acceptable contraceptive method prevent pregnancy . 12 . Presence febrile illness within 24 hour admission acetaminophen use wear CGM . The subject may reschedule Research House/hotel admission criterion meet . The camp study subject participate trial condition meet . 13 . Medical psychiatric condition judgment investigator might interfere completion protocol : Inpatient psychiatric treatment past 6 month Uncontrolled adrenal insufficiency Alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>Artificial Pancreas Project ( APP )</keyword>
	<keyword>Diabetes Assistant ( DiAs )</keyword>
	<keyword>Closed-Loop Control ( CLC )</keyword>
	<keyword>Continuous Glucose Monitor ( CGM )</keyword>
	<keyword>Insulin Pump</keyword>
</DOC>